Organ-Threatening or Life-Threatening GPA: Managing Disease Refractory to Initial Induction Therapy

This protocol is for patients with organ-threatening or life-threatening granulomatosis with polyangiitis (GPA) whose disease has not responded adequately to first-line induction — patients where initial treatment has failed to achieve the remission goal and a structured next step is required.

Prior Treatment Line & Failure Condition

The first-line induction approach combined glucocorticoids with either rituximab or cyclophosphamide. The defined goals were full remission — absence of typical signs, symptoms, and other features of active disease — and sustained remission maintained across the subsequent maintenance period.

When that induction and maintenance strategy does not achieve or sustain these targets, the disease is considered refractory and escalation to this next management step is indicated.

Clinical Scenario

The patient continues to present with GPA at the organ-threatening or life-threatening severity level, now with documented failure to meet the remission criteria set for prior therapy. A reassessment and a different or augmented management strategy are needed.

Next-Step Management — Partial Overview

The approach at this stage starts with a thorough reassessment of disease status and comorbidities. Options under consideration may include switching between or combining the immunosuppressive agents used in the prior line, as well as additional interventions for persistent disease manifestations — particularly where infection risk is a concern.

Management in close conjunction with, or referral to, a centre with expertise in vasculitis is recommended. The complete structured regimen — all options, clinical decision points, and supporting evidence — is available in the full protocol.

Treatment Goal

The target remains remission of active GPA, defined as the absence of typical signs, symptoms, or other features of active disease.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2022-223764

For induction of remission in patients with new-onset or relapsing GPA or MPA with organ-threatening or life-threatening disease, we recommend treatment with a combination of glucocorticoids and either rituximab or cyclophosphamide.

For patients with GPA or MPA with disease refractory to therapy to induce remission, we recommend a thorough reassessment of disease status and comorbidities and consideration of options for additional or different treatment.

These patients should be managed in close conjunction with, or referred to, a centre with expertise in vasculitis.

The combination of RTX and CYC is used in patients with refractory organ-threatening or life-threatening disease by many centres, but data on this approach in true refractory AAV are lacking.

Adding intravenous immunoglobulins can be an option for persistent disease manifestations, particularly in patients with increased risk of infection.

View source ↗